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Promoting Recruitment using Information
Management Efficiently (PRIME): a stepped-
wedge, cluster randomised trial of a
complex recruitment intervention
embedded within the REstart or Stop
Antithrombotics Randomised Trial
Amy E. Maxwell1, Richard A. Parker3, Jonathan Drever1, Anthony Rudd2, Martin S. Dennis1, Christopher J. Weir3
and Rustam Al-Shahi Salman1*
Abstract
Background: Few interventions are proven to increase recruitment in clinical trials. Recruitment to RESTART, a
randomised controlled trial of secondary prevention after stroke due to intracerebral haemorrhage, has been
slower than expected. Therefore, we sought to investigate an intervention to boost recruitment to RESTART.
Methods/design: We conducted a stepped-wedge, cluster randomised trial of a complex intervention to
increase recruitment, embedded within the RESTART trial. The primary objective was to investigate if the PRIME
complex intervention (a recruitment co-ordinator who conducts a recruitment review, provides access to bespoke
stroke audit data exports, and conducts a follow-up review after 6 months) increases the recruitment rate to
RESTART. We included 72 hospital sites located in England, Wales, or Scotland that were active in RESTART in
June 2015. All sites began in the control state and were allocated using block randomisation stratified by hospital
location (Scotland versus England/Wales) to start the complex intervention in one of 12 different months. The
primary outcome was the number of patients randomised into RESTART per month per site. We quantified the
effect of the complex intervention on the primary outcome using a negative binomial, mixed model adjusting for
site, December/January months, site location, and background time trends in recruitment rate.
Results: We recruited and randomised 72 sites and recorded their monthly recruitment to RESTART over 24 months
(March 2015 to February 2017 inclusive), providing 1728 site-months of observations for the primary analysis. The
adjusted rate ratio for the number of patients randomised per month after allocation to the PRIME complex intervention
versus control time before allocation to the PRIME complex intervention was 1.06 (95% confidence interval 0.55 to 2.03,
p = 0.87). Although two thirds of respondents to the 6-month follow-up questionnaire agreed that the audit reports were
useful, only six patients were reported to have been randomised using the audit reports. Respondents frequently
reported resource and time pressures as being key barriers to running the audit reports.
(Continued on next page)
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Conclusion: The PRIME complex intervention did not significantly improve the recruitment rate to RESTART. Further
research is needed to establish if PRIME might be beneficial at an earlier stage in a prevention trial or for prevention
dilemmas that arise more often in clinical practice.
Keywords: Methodology, Recruitment, Study within a trial, Stepped-wedge trial, Cluster randomised trial, Audit, Complex
intervention
Background
Under-recruitment to randomised controlled trials (RCTs)
is a major source of inefficiency in the conduct of applied
clinical research [1]. Slow recruitment delays the delivery
of research and increases costs by increasing the number
of staff and sites or by extending the amount and duration
of funding required. If a trial extension is not possible,
then under-recruitment will increase the likelihood of fail-
ing to detect a clinically relevant intervention effect if it
exists, which may prevent patients from benefiting from a
potentially efficacious intervention. This problem is exten-
sive in clinical trials research – a review of 73 RCTs
funded by the Medical Research Council (MRC) or Health
Technology Assessment (HTA) in the UK in 2002–2008
found that almost half of the RCTs did not recruit their
originally specified target sample size and nearly half of
the RCTs received an extension of some kind [2].
The REstart or STop Antithrombotics Randomised Trial
(RESTART, ISRCTN71907627, www.RESTARTtrial.org) is
an on-going RCT comparing policies of restarting versus
avoiding antiplatelet drugs for secondary prevention after
stroke due to intracerebral haemorrhage (ICH), which
aimed to recruit 720 participants over 2 years (from May
2013 to May 2015) based on recent epidemiological data
[3, 4]. RESTART has been behind its recruitment targets
despite implementing as many as possible of the strategies
that have been shown to maximise recruitment [3, 5–7] in-
cluding minimising the number of eligibility criteria and
maximising the time window for recruiting patients after
ICH onset.
The aim of the Promoting Recruitment using Information
Management Efficiently (PRIME) trial was to investigate
whether the rate of randomisation of patients to RESTART
could be increased by means of a complex recruitment
intervention applied to sites through which investigators in
secondary care, with the support of a recruitment co-
ordinator, used electronic patient records held by national
stroke audits to identify potentially eligible patients.
Methods/design
Design and setting
PRIME is a closed-cohort, stepped-wedge, cluster rando-
mised trial investigating a complex intervention to boost
recruitment in RESTART. PRIME is an embedded
recruitment trial within the RESTART parallel-group
randomised trial. The stepped-wedge design involved
a sequential roll out of the PRIME complex interven-
tion to clusters (active hospital sites in RESTART)
over twelve 1-month time periods [8]. The PRIME
trial is an example of a closed-cohort, stepped-wedge
trial because all sites at the start of the trial were ex-
pected to continue until the end of the study and no
new sites were to be added [9]. All sites began in the
control state (no intervention). The month in which
the sites started the PRIME complex intervention was
randomly allocated so that groups of sites began the
intervention sequentially at equally spaced time intervals
(steps) as shown in Fig. 1.
Complex recruitment intervention
The PRIME complex intervention involved a recruit-
ment co-ordinator discussing ways to improve recruit-
ment to RESTART at each site via teleconference with
the principal investigator and/or the local team, focus-
sing on the provision of software for each site with in-
structions on how to extract from national stroke audit
data lists of their own patients who were potentially eli-
gible for RESTART. There was then a second teleconfer-
ence to review progress 6 months later. We sent each
site a questionnaire before the recruitment review and
then a follow-up questionnaire before the 6-month
follow-up review. Full details of the PRIME complex
intervention, along with inclusion/exclusion criteria and
the sample size calculation can be found in the PRIME
protocol publication [10].
We created bespoke stroke audit data exports for
PRIME in collaboration with the Scottish Stroke
Care Audit (SSCA) and the Sentinel Stroke National
Audit Programme (SSNAP) teams, to reflect the
RESTART eligibility criteria as closely as possible.
We provided sites with instructions on how to
produce these exports once they had received their
recruitment review. Further details can be found in
the PRIME protocol [10].
Each audit database produced two bespoke RESTART
audit reports (short and long) which could be run
separately. The short reports for both were most
likely to have suitable patients for RESTART whilst
the long reports widened the criteria, and contained
further potentially eligible patients. Once the reports
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were generated the site staff checked that the patient
met all the eligibility criteria, using the patient’s medical
records and/or via their general practitioner.
The 6-month follow-up questionnaire asked sites to
collect information on the number of patients randomised
directly from the audit reports.
Site recruitment
Active hospital sites in RESTART were invited to take part
in PRIME in June 2015. There were 109 active hospital
sites in the RESTART collaboration in the UK at that time.
Twenty-four were excluded: two sites in Northern Ireland
(where stroke audit data collection was not consistent);
two sites in Scotland and two sites in England that
piloted the bespoke stroke audit data exports; 14
sites recently activated to RESTART in 2015 (to
ensure that all sites taking part had several months
recruiting before receiving the intervention); and the
remaining four excluded sites were unsuitable for
other reasons. The PRIME recruitment co-ordinator
telephoned the local RESTART co-ordinator at each
of the remaining 85 sites in ascending order of site
identification number to invite them to take part in a
‘recruitment review’, following up by email if re-
quired, until the sample size target of 72 sites agreed,
as shown in the PRIME complex intervention flow
chart (Fig. 2). Sites were not informed about the
exact content of the recruitment review or that its
timing would be randomly allocated. The recruitment
co-ordinator and staff at each participating site
remained blinded to the timing of the recruitment
review until 2 months before the month allocated for
each site’s review, when this had to be revealed in
order to organise the review.
Randomisation
We used stratified block randomisation to randomly allo-
cate the 72 sites into 12 groups of six sites each, with strati-
fication by hospital location (Scotland vs. England/Wales)
to ensure that the proportions of sites with access to each
national stroke audit data source were approximately con-
sistent across the 12 groups. A programmer independent
of the trial created the computer-generated random alloca-
tion sequence and sent this list to the trial data manager
who then informed the recruitment co-ordinator at the
required times for them to arrange the review.
A timeline cluster diagram is shown in Fig. 3 to clarify
the timing of trial processes and blinding.
Statistical methods
Full details of the statistical methodology can be found
in the published Statistical Analysis Plan [11]. Briefly,
the primary outcome of recruitment rate per site per
month was analysed using a negative binomial general-
ised linear mixed model (GLMM), including the fixed-
effect explanatory variables: number of months since
start of the embedded PRIME study (represented by a
linear term in the model to adjust for any background
changes in trial recruitment rate), season (December/
January versus all other months), site location (Scotland
versus England/Wales), and an indicator variable for
whether the complex intervention was due to have been
implemented or not (according to the planned random-
isation schedule). Site was also included as a random ef-
fect in the model.
The primary analysis followed an ‘as-randomised’
intention-to-treat principle, which meant that we ana-
lysed the data according to the allocated timing of the
recruitment review, rather than the time that the
Fig. 1 The Promoting Recruitment using Information Management Efficiently (PRIME) stepped-wedge trial design
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recruitment review actually occurred. In addition, for
the primary analysis, all 72 sites were included regardless
of any site withdrawals or site suspensions or compli-
ance with the PRIME trial procedures. For sites that
were suspended (i.e. not permitted to recruit patients
due to the principal investigator leaving or another
reason), their missing observations were imputed as ‘0’
patients randomised. This was believed to be an appro-
priate imputation since it is likely, based on the reasons
for suspension (e.g. due to the principal investigator
being off sick), that many of these sites who were
suspended would have failed to randomise any patients
if they remained in the trial, and also ‘0’ was by far the
most frequently observed number of patients rando-
mised per month. However, to check the robustness of
this assumption and the impact of any deviations from
the protocol, a per-protocol secondary analysis was per-
formed after excluding any sites experiencing permanent
suspensions or sites failing to receive either the initial
recruitment review or the 6-month follow-up review.
Results
The PRIME Consolidated Standards of Reporting
Trials (CONSORT) flow diagram is shown in Fig. 4.
Seventy-two sites were randomised to PRIME; of
which 64 (89%) were located in England and Wales
and eight (11%) in Scotland. Sixty-four sites (89%) re-
ceived a recruitment review and 55 (76%) received
both a first recruitment review and 6-month follow-
up review.
Fig. 2 The Promoting Recruitment using Information Management Efficiently (PRIME) complex intervention flow chart
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Fig. 3 The Promoting Recruitment using Information Management Efficiently (PRIME) Timeline cluster diagram
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Recruitment review
The median delay between the scheduled randomised
time of review (first day of the month allocated) and
the actual time the recruitment review was delivered
was 11.5 days (interquartile range (IQR) 8 to 19.75
days; range 0–71 days). In the 6-month period before
any site received the PRIME complex intervention
(March 2015 to August 2015), the total number of
patients randomised was 0 for 47 sites (65%), 1 for
18 sites (25%), 2 for 6 sites (8%), and 3 for 1 site
(1%).
Every time the recruitment review was conducted, we
recorded whether there were any issues which impacted
the PRIME complex intervention delivery. For 10 sites
(14%), the sound quality for the teleconference was quite
poor and for two sites (3%) it was very poor. This was due
to a mixture of reasons including, sites using speaker
phones and separate phones being used in the same room
Fig. 4 Consolidated Standards of Reporting Trials (CONSORT) 2010 flow diagram
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causing echo. For nine sites (12%) the principal investiga-
tor was absent from the review, and for three recruitment
reviews (4%) the research co-ordinator was ill which may
have affected delivery. For the 48 remaining sites (67%),
we delivered the recruitment review with no issues.
Table 1 shows responses from the pre-recruitment
review questionnaire. Eighteen sites (32%) were already
using stroke audit data to recruit to RESTART; the most
popular information source to identify eligible patients
was screening logs (40 sites, 71%).
A complete summary of baseline site characteristics
and responses to the pre-review questionnaire stratified
by randomised group are shown in Additional file 1.
Primary outcome
The change in the cumulative randomisation total (pri-
mary outcome) over time is shown in Fig. 5, with shading
to indicate the number of sites that had actually received
the recruitment review (i.e. started the intervention) up to
that point. Separate plots for each of the randomised
groups of sites are shown in Additional file 2.
Following imputation of zero monthly counts for nine
suspended sites, each of the 72 sites contributed 24
months of observations (March 2015 to February 2017)
and so the full primary analysis dataset constituted N =
1728 site-months of observations. Seventy-eight site-
months (5%) were imputed with zero monthly counts
due to site suspensions.
Table 2 shows the results of the primary analysis on
the primary outcome. The adjusted rate ratio for the pri-
mary outcome (PRIME complex intervention versus
control condition) was estimated to be 1.06 (95% confi-
dence interval 0.55 to 2.03, p = 0.87) after adjusting for
site, December/January months, site location (Scotland
versus England and Wales), and time in months since
the start of the embedded study.
Per-protocol analysis
Nine sites were permanently suspended during the
PRIME study period and, therefore, these sites were ex-
cluded from the per-protocol analysis, as were 11 other
sites who, for whatever reason, did not receive either a
first recruitment review or a 6-month review. After
restricting the analysis to the per-protocol population of
sites, the adjusted rate ratio became 1.01 (0.50 to 2.04,
p = 0.98).
Sensitivity analyses
The results were very similar and conclusions unchanged
after performing other pre-specified sensitivity analyses
(see Additional file 3). In particular, after restricting the
analysis to the intervention roll-out period only (September
2015 to July 2016), the adjusted rate ratio became 1.07
(0.54 to 2.13, p = 0.84). Fitting a second-order spline
function to model any secular changes over time improved
the precision of estimation and reduced the width of the
confidence interval slightly, but there was no change to the
conclusions (RR 1.06, 95% CI 0.58 to 1.92, p = 0.86).
Follow-up questionnaires
Fifty-one out of 72 sites (71%) returned the 6-month
follow-up questionnaire, and 30 of these (59%) were known
to have generated and used the audit data extract reports.
Table 1 Responses from the pre-recruitment review
questionnaires
Approximate proportion of inpatients, who are suitable
for follow-up, seen in clinic after hospital discharge
0% 5 (12%)
10–30% 5 (12%)
60–90% 11 (26%)
100% 22 (51%)
Have you approached patients looked after by your
stroke unit in the past to invite them back to clinic
with a view to recruit them to RESTART?
No 20 (37%)
Yes 34 (63%)
Have you used the template invitation letter to invite
potential RESTART patients to clinic?
No 37 (62%)
Yes 23 (38%)
Are your stroke audit data complete and accurate to
the best of your knowledge?
No 1 (2%)
Yes 57 (98%)
Are you already routinely using the stroke audit data
to recruit to RESTART?
No 39 (68%)
Yes 18 (32%)
What other sources of information do you have on
patients which could be used to identify eligible
RESTART patients? [tick all that apply]
Screening logs 40 (71%)
A database other than the stroke audit 7 (12%)
Other 19 (34%)
No other information sources used (estimated based on
number answering previous question but not this one)
6 (11%)
Total number of sites in at least one of above four
categories
56
Have you used any other methods to boost recruitment?
No 22 (41%)
Yes 32 (59%)
Have you found any barriers to finding suitable patients
to recruit to RESTART?
No 8 (15%)
Yes 46 (85%)
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Out of the 30 sites using the audit reports, five sites
(17%) ‘strongly agreed’ that the reports were useful, 15
sites ‘agreed’ that the reports were useful (50%), eight
sites were ‘neutral’ (27%), and two sites ‘disagreed’ that
the reports were useful.
Sixteen sites (53%) indicated that they either had a
problem running or using the reports or listed disadvan-
tages to using the reports. The most common disadvan-
tage given was lack of time (seven sites, 23%); and a
further three sites (10%) had problems with resource is-
sues: for example, getting consultants or other staff to
run the reports or review medical notes. Five sites (17%)
complained that the procedure was not identifying many
extra patients beyond those already screened as inpa-
tients. Four sites (13%) specified that the reports were
picking up a high number of ineligible patients and pa-
tients who had died. Two other sites (7%) were con-
cerned about accuracy of the reports, indicating that
‘patients who are already in the trial are not in the list’,
and ‘[some patients] weren’t a bleed at all’.
One site that used the audit reports made a sugges-
tion for improvement: they wrote that they would
have liked to have had ‘more information regarding
understanding the report once produced, and how to
link ID numbers to actual patients’.
Twenty-one sites answered ‘no’ to the question of
whether they extracted and used the audit data ex-
tract reports. The most common barrier cited was re-
source/staffing/time issues (10/21, 48%); followed by
use of other screening methods to identify RESTART
patients (6/21, 29%); and problems running the re-
ports or accessing the SSNAP database (6/21, 29%).
Where sites did create audit reports, these were run
to an average of 3 years back (range 0.5–6 years) (see
Table 3). Seventeen sites (68%) ran the audit reports
once; seven sites ran the reports twice (28%); and one
site ran the reports three times.
Summary statistics for the number of patients identi-
fied by the reports, numbers invited back to clinic and
numbers responding are shown in Table 3. Sites had the
option to record their answers split by audit report (i.e.
short and long), or if preferred, they had the option to
record the combined total using the ‘Both’ category.
The number of eligible patients invited to a screening
visit, declining to come to a screening visit, and numbers
randomised is shown in Table 4.
Under the ‘Short’ report category, two sites each re-
ported one patient coming back to clinic; both patients
were randomised. Under the ‘Long’ report category, one
site reported a single patient coming back to clinic, but
the patient was not randomised by the time of the 6-
month questionnaire. Under the ‘Both’ category, the site
with two patients coming back to clinic randomised one
of them, and the site with three patients coming back to
clinic managed to randomise all three of them. There-
fore, the total number of patients randomised was six
(half of whom were randomised through a single site).
Although it should be noted, for this particular site, the
data collected on the 6-month questionnaire was not
Fig. 5 Change in cumulative randomisation total over time, with darker shading indicating more sites receiving the recruitment review
Table 2 Negative-binomial generalised linear mixed model
(GLMM) results for the primary analysis of the primary outcome
(N = 1728, 72 sites)
Variable Rate
ratio
95%
confidence
interval
p value
Intervention (reference category:
control condition)
1.06 0.55 to 2.03 0.870
Time since start of study
(per month)
0.98 0.93 to 1.02 0.336
December/January (reference
category: any other month)
0.55 0.288 to 1.05 0.071
Site location in Scotland (reference
category: location in England or Wales)
2.00 0.96 to 4.2 0.063
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from the bespoke audit data reports – they extracted a
list of all ICH patients from the national audit data.
Discussion
We found insufficient evidence that a complex interven-
tion involving a recruitment review and using audit re-
ports to search electronic records had a substantial impact
on increasing recruitment to the RESTART trial. The
point estimate of the rate ratio was close to 1 in the pri-
mary analysis and in all sensitivity analyses, including the
per-protocol analysis. The corresponding 95% confidence
limits indicate that a large intervention effect of rate ratio
2 or above is unlikely. Although most respondents (67%)
to the 6-month questionnaire agreed that the audit reports
were useful, only six patients in total were reported to
have been randomised from the audit reports.
Table 3 Summary statistics for non-categorical responses to questions in the 6-month post-recruitment review questionnaire. Sites
used short, long, or both types of bespoke RESTART audit reports
Valid number of site responses Median Interquartile range (IQR) Minimum Maximum
How far back did you run the reports? (years) 28 (93%) 3.0 2.1 to 3.9 0.5 6
The number of patients identified by the audit
reports
Short 20 (67%) 17.5 8.75 to 84.50 3 273
Long 13 (43%) 26.0 16.5 to 96.0 2 787
Both 8 (27%) 45.5 16.25 to 236.25 10 376
The number of eligible patients identified by the
audit reports
Short 20 (67%) 1.0 0 to 4.0 0 25
Long 12 (40%) 0.5 0 to 2.5 0 15
Both 6 (20%) 4.5 0 to 8.75 0 11
The percentage of patients who were actually
eligible out of all those identified by the
audit reports
Short 19 (63%) 4.0% 0 to 22.2% 0 100%
Long 12 (40%) 2.0% 0 to 9.8% 0 50%
Both 6 (20%) 4.5% 0 to 27.1% 0 50%
The number of eligible patients that the site
contacted for sites identifying at least one
eligible patient
Short 12 (40%) 0.5 0 to 2.75 0 15
Long 5 (17%) 1.0 0 to 2.5 0 4
Both 5 (17%) 5.0 0 to 8.0 0 10
The percentage of patients who were actually
contacted out of all those eligible for sites
identifying at least one eligible patient
Short 12 (40%) 25% 0 to 100% 0 100%
Long 5 (17%) 33.3% 0 to 100% 0 100%
Both 5 (17%) 62.5% 16.7% to 95.5% 0 100%
The number of eligible patients responding for
sites contacting at least one patient
Short 9 (30%) 0 0 to 1.0 0 15
Long 7 (23%) 0 0 to 0 0 2
Both 5 (17%) 1.0 0 to 7.0 0 10
The percentage of patients responding out of
all those contacted for sites contacting at least
one patient
Short 9 (30%) 0% 0 to 75% 0 100%
Long 7 (23%) 0% 0 to 0% 0 50%
Both 5 (17%) 66.7% 0 to 100% 0 100%
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Since a detailed protocol was used to ensure fidelity to
the intervention; and since 89% of sites received at
least the first recruitment review and over 75% of
sites received both reviews, the lack of intervention
effect was unlikely to be due to failure to implement the
intervention successfully. Indeed, even after removing
sites that did not follow the protocol, no significant inter-
vention effect was found.
There may be several reasons for the lack of evidence
of an intervention effect. First, many sites reported a
lack of time and resources to sufficiently search the audit
data and use the bespoke audit reports. These issues
were also raised as disadvantages by those sites who ran
the audit reports. Secondly, it could be that the complex
intervention itself was simply not effective. Our second-
ary outcome data suggested that the median percentage
of patients identified by the audit reports that were eli-
gible was low: less than 5%. Also the complex interven-
tion did not include any face-to-face contact with the
site, which may have reduced its effectiveness. The Study
Within a Trial-1 (SWAT-1) study provided evidence of
the effectiveness of an intervention involving a face-to-
face site visit combined with scheduled meeting on re-
cruitment rates in a multi-centre randomised trial. How-
ever, the findings of this study should be interpreted
with caution due to the relatively weak study design (it
was a non-randomised before-and-after study), and
hence the potential for confounding bias [12].
Besides targeting the local site teams involved in recruit-
ment, interventions could also be devised to target poten-
tially eligible patients directly. Interestingly, a text-message
intervention to potentially eligible participants stating that
there was only a limited number of places left to join the
‘txt2stop’ smoking cessation trial was found to be effective
in increasing recruitment rates compared to a text mes-
sage with no such scarcity message content [13]. More
recently, a cross-factorial, embedded RCT design within
the EQUIP trial was used to investigate the effect of an
intervention involving advertising patient and public
involvement to boost recruitment rates. However, the
authors found that the intervention had no significant
effect on recruitment rates [14].
Strengths and limitations
A strength of our embedded recruitment trial is that it
has a cluster randomised design. Stepped-wedge or
parallel-group cluster randomised designs are preferable
to alternative non-randomised designs, such as before-
and-after studies, because they are less susceptible to
confounding bias due to temporal trends [15]. In cases
where the potential harms or burden due to an interven-
tion are known to be low, then the stepped-wedge de-
sign should be considered because all clusters receive a
potentially efficacious intervention, and the trial may be
more efficient compared to a parallel-group cluster trial.
For recruitment trials embedded in multi-centre trials, it
may be expected that there is a high level of heterogen-
eity in recruitment rates between sites due to substantial
differences in site size and, therefore, a stepped-wedge
trial design may confer greater power.
A limitation of our study is that the PRIME complex
intervention was only implemented by a single recruit-
ment co-ordinator which may limit the generalisability
of results to other trials and settings. Even so, a detailed
protocol was followed, so it is unlikely that this was a
major limitation. The most important factor limiting
generalisability was the fact that PRIME was embedded
within a single host trial. If the intervention was imple-
mented in other trials and settings the results may have
been different.
In contrast, the START programme [16] was designed
to test two recruitment interventions consisting of (1)
optimised patient information sheets and (2) multimedia
approaches to encourage patient involvement in research,
across multiple host trials, which has provided more gen-
eralisable results compared to confining a recruitment
intervention to a single host trial. The START investiga-
tors showed that an optimised patient information sheet
did not significantly improve recruitment or retention
rates into the REFORM trial [17].
A second but less important limitation relates to the
6-month follow-up questionnaire results. There was a
limited response rate from sites to the first page of the
6-month questionnaire asking for number of patients
randomised from the audit reports, which suggests that
there may have been randomisations that resulted from
the audit reports that were not recorded. Moreover,
some sites reported that they were still working through
the lists at the time of the 6-month review. Therefore,
the self-reported results of the numbers randomised
from the audit reports may only represent partial infor-
mation. It should also be noted that for at least a few
sites, the numbers given were from other lists of patients
(apart from the audit reports) and some sites accessed
Table 4 Number of patients reported to have come back to
clinic and numbers randomised from the audit reports. Sites
used short, long, or both types of bespoke RESTART audit
reports
The number of
eligible patients
who came to a
screening visit
The number of eligible
patients who declined
to come to a screening
visit
The number of
patients who
were randomised
directly from the
audit reports
0 1 2 3 0 1 2 ≥3 0 1 2 3
Short 8 2 0 0 11 0 0 0 8 2 0 0
Long 6 1 0 0 6 1 0 0 6 0 0 0
Both 3 0 1 1 2 2 0 1 4 1 0 1
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the audit data directly without using the bespoke audit
reports, albeit this could still be regarded as an indirect
consequence of the intervention.
Implications for further research
Although our study showed no significant effect of the
PRIME complex intervention, this does not necessarily
mean that similar recruitment interventions involving
searching electronic patient records will not be effective in
other trials or settings. Indeed, in primary care, using
electronic patient records has been shown to boost
recruitment to ongoing RCTs [18, 19]. Further work
is needed to establish the effectiveness of using electronic
patient records in secondary care. Alternative ways to
increase recruitment may also need to be investigated,
particularly those which minimise impact on clinician
time and resources.
Conclusions
We found insufficient evidence that the PRIME complex
intervention is effective in increasing the recruitment
rate to RESTART, despite the intervention being suc-
cessfully implemented in the majority of sites. Further
research is needed into methods to boost recruitment in
trials in secondary care.
Trial registration
PRIME was registered with the Northern Ireland Hub for
Trials Methodology Research SWAT repository (SWAT22,
http://bit.ly/2a4n7Yb) on 23 December 2015 and was sub-
mitted to the Online Resource for Recruitment research in
Clinical trials (ORRCA, www.orrca.org.uk).
Trial status
The host trial, RESTART, aimed to recruit 720 partici-
pants over 2 years, from May 2013 to May 2015 based on
recent epidemiological data [3, 4]. Due to under-
recruitment, RESTART’s funder granted an extension of
recruitment until 31 May 2018. The trial end date is Feb-
ruary 2019. PRIME’s first recruitment review took place in
September 2015 and the last review completed in August
2016. The first 6-month follow-up review took place in
March 2016 and the last one completed in February 2017.
After the final 6-month follow-up was received there was
a period of 3 months to analyse the data, meaning that
PRIME completed in May 2017.
Additional files
Additional file 1: Baseline site characteristics and responses to the
pre-review questionnaire. (PDF 494 kb)
Additional file 2: Separate plots of each of the randomised groups of
sites. (PDF 421 kb)
Additional file 3: Sensitivity analyses of the primary outcome. (PDF 278 kb)
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